Last mentioned: 3d ago
Clinical Guidance
Expected release of preliminary federal protocols for detransition medical management.
Regulatory Review
Anticipated commencement of HHS review into federal funding for gender-affirming clinics.
FDA Type B Meeting
Planned follow-up meeting to define the Phase III pathway for AMT-130 in Huntington's disease.
AMT-260 Data
Clinical data expected from the Phase I/IIa study in refractory mesial temporal lobe epilepsy.
Policy Announcement
Assistant Secretary Brian Christine declares detransition care a top priority for HHS.
Initial Inquiry
The Senator's office begins requesting data on DMD drug approval timelines and internal CBER deliberations.
Investigation Announced
Sen. Ron Johnson announces a formal probe into the FDA's handling of rare disease drug applications.
Commissioner Meeting
Johnson meets with FDA Commissioner Marty Makary to discuss specific biologic therapy rejections.
Q4 2025 Earnings
Company reports 25% total revenue growth and progress in clinical diagnostic pivot.
Earnings Release
Company announces 2025 results and provides update on FDA Type A meeting.
FDA U-Turn
FDA agrees to review the application after resolving the public dispute.
Political Controversy
Reports emerge that the vaccine chief overruled career scientists to block the shot.
FDA 510(k) Submission
Premarket notification submitted for Lucent AD Complete diagnostic test.
Refusal to File
FDA issues a shocking rejection of the application, sparking a public dispute.
CMS Reimbursement Milestone
CMS approves $897 reimbursement rate for Lucent AD Complete, establishing a national reference price.
Fiscal Year End
uniQure closes 2025 with $622.5M in cash and equivalents.
Initial BLA Submission
Moderna submits its Biologics License Application for mRNA-1010.
Assay Portfolio Expansion
Launch of 13 new assays including pTau-205 and pTau-212 for neurodegenerative research.
HHS Assistant Secretary Brian Christine has announced that detransition care will become a primary focus for the department, marking a significant pivot in federal healthcare policy. This shift is expected to influence clinical guidelines, pharmaceutical regulation, and federal funding for gender-related medical interventions.
Senator Ron Johnson (R-Wisc.) has launched an investigation into the FDA's regulatory hurdles for rare disease treatments, specifically targeting biologics for Duchenne muscular dystrophy. The probe follows a direct meeting with FDA Commissioner Marty Makary and signals a significant escalation in political pressure on the agency's approval standards.
The head of the FDA’s vaccine division is stepping down for the second time, marking a significant leadership vacuum at a critical juncture for the agency. This departure follows a period of intense scrutiny and reported friction between the regulatory body and the Trump administration over vaccine authorization protocols.
Quanterix reported Q4 2025 revenue of $43.9 million, driven by a 25% year-over-year increase and significant progress in its Alzheimer’s diagnostic portfolio. Despite organic declines in its core Simoa and Spatial segments, the company secured a $897 CMS reimbursement rate for its Lucent AD Complete test and submitted its 510(k) to the FDA.
uniQure reported a robust $622.5 million cash position, extending its operational runway into late 2029. While clinical data for its Huntington’s disease candidate AMT-130 remains strong, the company is still seeking regulatory alignment with the FDA on a definitive Phase III pathway.
Moderna has confirmed that the FDA will officially review its mRNA-based influenza vaccine following a highly publicized regulatory standoff. The reversal comes after reports that the Trump administration's vaccine leadership initially overruled career scientists to block the application.